Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 14-3-2012
  • E-pubdatum
  • 14-3-2012
  • Bron
  • Medische Oncologie

Systematische beoordeling van oncologische middelen

De commissie BOM, in het leven geroepen door de NVMO, heeft de systematiek en criteria voor beoordeling van oncologische middelen (PASKWIL 2000) herzien en zal met ingang van 2012 op deze vernieuwde wijze de beroepsgroep blijven adviseren over de plaats van nieuwe oncologische middelen (en nieuwe oncologische behandelingen) in de dagelijkse praktijk.

Referenties

  1. Willemse PH, Rodenburg CJ, Otter R. Een toetssteen voor besluitvorming: nieuwe criteria voor registratie oncologische middelen. Med Contact 2001;56(20):794-6.
  2. Willemse PH, Tjan-Heijnen VC. Difficult decisions in the costeffectivieness analysis of new cancer treatments. Eur J Hosp Pharm 2009;15(4):50-3.
  3. Floriani I, Garattini S, Torri V. Looking for efficiency rather than efficacy in randomized controlled trials in oncology. Ann Oncol 2010;21(7):1391-3.
  4. Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist 2010;15 suppl 1:19-23.
  5. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumour KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-9.
  6. Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12(7):642-53.
  7. McCain JA. The ongoing evolution of endpoints in oncology. Manag Care 2010;19(5). 
  8. Trotta F, Leufkens HGM, Schellens JHM, et al. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol 2011;29(16):2266-72.
  9. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63(8):e1-37.
  10. Van Cutsem EV, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17.
  11. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64.
  12. Guyatt GH, Oxman AD, Kunz R, et al. What is ‘quality of evidence’ and why is it important to clinicians? BMJ 2008;336(7651):995-8.